DB05293ExperimentalSmall molecule
IDM-2 is composed of Monocyte-derived Activated Killer (MAK) cells. IDM produces MAK cells from the patient's own white blood cells by activating these cells ex vivo to allow them to...
- Mechanism
- Curator reviewed
MAK cells are produced ex-vivo from macrophages taken from the patient that are activated with the use of gamma interferon, a synthetic version of a natural activator. Following surgery for bladder cancer, IDM-2 is instilled directly into the bladder.
- Primary indication
- Investigated for use/treatment in bladder cancer.Curator reviewed
What you can answer from here — as of April 02, 2025
Which companies are running trials of IDM-2, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account